Opentrons Labworks has raised 40 million dollars in a Series E financing led by healthcare investor Avego, with additional investment from BroadOak Capital Partners. Existing investors include SoftBank Vision Fund and Khosla Ventures. The New York based company said the capital will scale its robotics, software and data infrastructure tools, and fund systems in which AI and robots design, execute and learn from experiments in a continuous loop.
The pitch rests on an installed base rather than a prototype. Opentrons says it has deployed more than 11,000 robots to laboratories in over 80 countries, including at most of the top 20 global pharmaceutical companies and every top 20 United States research university, on its own account. Its Flex platform combines the robots with software and AI systems intended to design an experiment, run it, and improve the next iteration from the results, generating structured, reproducible data from every run.
That positions the company differently from a pure instrument vendor. If experiments run on a common, open, API driven platform, the protocols and the data they produce become standardised, which is what AI models need to move from predicting biology to directing physical work. The Series E money goes to that layer: AI driven experiment execution, faster protocol development, deeper integration with other laboratory systems and entry into new markets.
The unverified part is the conversion. A large fleet of relatively low cost robots does not by itself prove that AI generated protocols run reliably at scale, or that users will pay software and data prices for a platform they adopted as open hardware. The financing gives Opentrons the capital to make that case, and it arrives in the same week as a nine figure scale data licensing effort in immunology, which together show where private capital in life sciences tools is concentrating: on the infrastructure that makes experiments machine readable.